Siemens Healthineers AG
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bernhard Montag
- Full Time Employees
- 74,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Siemensstr. 3 Forchheim BV Germany 91301
- IPO Date
- Mar 16, 2018
- Website
- siemens-healthineers.com
- Similar Companies
- Business
- Siemens Healthineers AG (SHL.DE) develops, manufactures and markets diagnostic and therapeutic products and services for healthcare providers worldwide; core offerings span Imaging with magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging and ultrasound devices; Diagnostics encompassing in-vitro testing including clinical chemistry analyzers, immunoassay systems, hematology, coagulation, urinalysis, blood gas analysis and molecular diagnostics; Varian segment providing multi-modality cancer care technologies, radiation oncology solutions and integrated digital workflows; Advanced Therapies featuring angiography systems, mobile C-arms and image-guided therapies; plus digital health services such as artificial intelligence in radiology, health data analytics, telemedicine platforms and workflow optimization tools. The company operates globally across Americas, Europe, Asia-Pacific, Middle East and CIS regions through approximately 72,000 employees, generating around €22 billion in revenue in fiscal year 2024 with key segments including Imaging at €11.8 billion, Diagnostics at €4.4 billion, Varian at €3.8 billion and Advanced Therapies at €2 billion. Headquartered in Forchheim near Erlangen, Germany with registered office in Munich, Siemens Healthineers traces its roots to 1847 as part of Siemens AG, which retains a 75% stake following the 2017 spin-off and 2018 IPO; it serves hospitals, clinics, laboratories and oncology centers with solutions influencing nearly three-quarters of critical clinical decisions. Recent developments include the December 2024 completion of its €200 million-plus acquisition of Novartis' Advanced Accelerator Applications Molecular Imaging business, adding 13 European radiopharmacies in France, Spain, Portugal, Italy and Germany plus a workforce of 420 to bolster PETNET Solutions' network for diagnostic radiopharmaceuticals in oncology, neurology and cardiology; a May 2025 announcement of $150 million U.S. investments in production expansion and job creation; and ongoing emphasis on AI integration and theranostics to drive precision medicine and growth in the €500 million PET sector projected to triple by 2033.
Company News
Siemens Healthineers AG (SMMNY) Discusses Foreign Exchange and Tariff Impacts on Q4 Revenue and Earnings Prepared Remarks Transcript
Sun Nuclear Announces Validated Adaptive QA Solution in Support of New Radiotherapy System, Accela, by Siemens Healthineers
Siemens Healthineers (OTCMKTS:SEMHF) Stock Price Down 0.4% – Here’s What Happened
Siemens Healthineers (OTCMKTS:SMMNY) Stock Price Down 0.2% – Here’s What Happened
Siemens Healthineers: Successful Investment, Updating For H2 2026
Siemens Healthineers AG (SMMNY) Q3 2026 Earnings Call Transcript
Siemens Healthineers Cuts Revenue Outlook on Diagnostics Weakness
Siemens Healthineers cuts revenue forecast citing diagnostics weakness
Siemens Healthineers AG (SMMNY) Discusses Q3 Pre-Close Updates: Foreign Exchange and Tariff Impacts on Revenue and Earnings Prepared Remarks Transcript
AiM Medical Robotics Announces Collaboration Agreement with Siemens Healthineers to Advance MRI-Guided Robotic Neurosurgery
Siemens Healthineers: Update Post The Carve-Out Announcement
Siemens Healthineers cuts 2026 outlook
Siemens Healthineers: Razor-And-Blades Model On A China-Driven Dip
CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results
Siemens Healthineers AG (OTCMKTS:SMMNY) Receives Average Rating of “Buy” from Brokerages
Siemens plans shareholder vote on Siemens Healthineers spin-off in February 2027
Siemens Healthineers AG (SMMNY) Discusses Q2 Pre-Close Outlook With Focus on Foreign Exchange and Tariff Headwinds Prepared Remarks Transcript
Siemens Healthineers AG (OTCMKTS:SMMNY) Receives Average Rating of “Buy” from Analysts
Imaginostics Receives Siemens Healthineers Letter of Support as Companies Advance Quantitative MRI Dialogue
Siemens Healthineers Launches Brain Health Research Portfolio with First Biomarker Assays Now Available